A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Latest Information Update: 14 Jun 2019
At a glance
- Drugs Ipafricept (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 04 Jun 2019 Results published in the Gynecologic Oncology
- 24 Jan 2018 Status changed to completed.
- 08 May 2017 Status changed from recruiting to suspended, according to an OncoMed Pharmaceuticals media release.